Table 1. Cohort characteristics.
| Variable | Deep ICH (n, %) | Lobar ICH (n, %) |
|---|---|---|
| Number of subjects | 245 | 265 |
| Age (mean, SD) | 69.9 (13.4) | 75.4 (10.6) |
| Female sex | 110 (0.45) | 133 (0.50) |
| Diabetes mellitus | 59 (0.24) | 48 (0.18) |
| Hypertension | 206 (0.84) | 183 (0.69) |
| Coronary artery disease | 57 (0.23) | 56 (0.21) |
| Atrial fibrillation | 47 (0.19) | 53 (0.20) |
| Hyperlipidemia | 49 (0.20) | 91 (0.34) |
| Previous ICH | 10 (0.04) | 24 (0.09) |
| Pre-ICH AIS / TIA | 39 (0.16) | 37 (0.14) |
| Pre-ICH dementia | 22 (0.09) | 50 (0.19) |
| Warfarin use | 49 (0.20) | 56 (0.21) |
| Antiplatelet therapy | 100 (0.39) | 106 (0.40) |
| Statin use | 62 (0.25) | 77 (0.29) |
| Probable / definite CAA | 0 (0) | 106 (0.40) |
| Possible CAA | 0 (0) | 159 (0.60) |
| GCS (median, IQR) | 14 (11 - 15) | 14 (12 - 15) |
| Time to baseline imaging in hours (median, IQR) |
5.9 (1.8 - 16.3) | 7.4 (1.3 - 21.9) |
| Baseline ICH volume (median, IQR) | 12.6 (1.9 - 28.5) | 18.6 (8.0 - 36.0) |
| Baseline IVH volume (median, IQR)* | 3.9 (1.0 - 21.0) | 2.8 (0.7 - 12.0) |
| Intraventricular extension | 120 (0.49) | 98 (0.37) |
| Interscan time in hours (median, IQR) | 17.6 (7.5 - 26.3) | 18.5 (8.2 - 29.2) |
| Follow-up ICH volume (median, IQR) | 13.7 (4.3 - 38.0) | 26.5 (10.8 - 36.0) |
| Follow-up IVH volume (median, IQR)* | 7.6 (2.5 - 25.0) | 6.5 (1.0 - 17.5) |
| Hematoma expansion (> 33%) | 24 (0.10) | 39 (0.15) |
| IVH expansion (> 2 cc)* | 29 (0.12) | 28 (0.12) |
| Death (90 days) | 81 (0.33) | 87 (0.33) |
| mRS: 0 – 2 (90 days) | 27 (0.11) | 32 (0.12) |
| APOE ε2 (minor allele frequency) | 0.08 | 0.11 |
| APOE ε4 (minor allele frequency) | 0.16 | 0.20 |
*
Data refers only to ICH cases with intraventricular extension and / or IVH expansion
ICH = Intracerebral Hemorrhage; n = number of patients; % = percentage; SD = standard deviation; AIS = acute ischemic stroke; TIA = transient ischemic attack; CAA = Cerebral Amyloid Angiopathy; GCS = Glasgow Coma Scale; IQR = interquartile range; IVH = intraventricular hemorrhage; mRS = modified Rankin Scale; APOE = Apolipoprotein E